Enliven Therapeutics (ELVN) EBIT (2019 - 2026)
Enliven Therapeutics (ELVN) posted EBIT of -$27.8 million for Q1 2026, up 18.85% sequentially from -$34.3 million in Q4 2025, and up 12.21% YoY from -$24.8 million in Q1 2025.
Enliven Therapeutics (ELVN) EBIT (2019 - 2026) Analysis & Trends
Enliven Therapeutics has reported EBIT for 8 years, with the latest figure at -$27.8 million in Q1 2026.
- Quarterly EBIT rose 12.21% year-over-year to -$27.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$115.8 million (down 5.01% YoY) and the FY2025 annual result came in at -$119.7 million, down 14.45% from the prior year.
- EBIT climbed to -$27.8 million in Q1 2026 per ELVN's latest filing, from -$34.3 million in the prior quarter.
- Over five years, EBIT peaked at -$8.7 million in Q1 2022 and troughed at -$34.3 million in Q4 2025.
- A 5-year average of -$22.0 million and a median of -$24.6 million in 2024 frame the typical range for EBIT.
- The sharpest annual moves came in 2022 and 2023: EBIT jumped 31.54% in 2022, then tumbled 123.64% in 2023.
- Over 5 years, EBIT stood at -$10.2 million in 2022, then tumbled by 123.64% to -$22.7 million in 2023, then fell by 18.33% to -$26.9 million in 2024, then fell by 27.47% to -$34.3 million in 2025, then advanced by 18.85% to -$27.8 million in 2026.
- According to Business Quant data, EBIT over the past three periods registered -$27.8 million, -$34.3 million, and -$25.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Enliven Therapeutics | 4.31 Bn | 3.41 Bn | - | -37.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -37.21 Mn |
| Mar 31, 2026 | -27.82 Mn |
| Dec 31, 2025 | -34.29 Mn |
| Sep 30, 2025 | -25.10 Mn |
| Jun 30, 2025 | -28.58 Mn |
| Mar 31, 2025 | -31.69 Mn |
| Dec 31, 2024 | -26.90 Mn |
| Sep 30, 2024 | -27.07 Mn |
| Jun 30, 2024 | -24.60 Mn |
| Mar 31, 2024 | -25.99 Mn |
| Dec 31, 2023 | -22.73 Mn |
| Sep 30, 2023 | -24.25 Mn |
| Jun 30, 2023 | -20.13 Mn |
| Mar 31, 2023 | -16.42 Mn |
| Dec 31, 2022 | -10.16 Mn |
| Sep 30, 2022 | -10.93 Mn |
| Jun 30, 2022 | -9.02 Mn |
| Mar 31, 2022 | -8.68 Mn |
| Dec 31, 2021 | -14.33 Mn |
| Sep 30, 2021 | -13.66 Mn |